Palladio Biosciences
BioTech/Drugs - Horsham, PA, US
Palladio Biosciences Employees
Palladio Biosciences Senior Management
Palladio Biosciences Details
Palladio Biosciences, Inc., is a Centessa company. Our first product, lixivaptan, is in Phase 3 clinical development for the treatment of autosomal polycystic kidney disease (ADPKD). ADPKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. It is the 4th leading cause of kidney failure and carries significant financial and emotional burden, affecting entire families. There is no cure for PKD. We are developing lixivaptan as a safe and effective agent to be used chronically to prevent the progression of PKD.
Website:
palladiobio.com
Employees:
20 - 49
HQ:
N/A
Location:
Horsham, PA, US
Revenue:
2.5 - 5 Million
Palladio Biosciences Technologies
Email Providers
Mimecast
Support and Feedback
Zendesk
Hosting
Google Cloud Hosting
Other
Microsoft Office 365